Altogether, these findings suggest that IL-10 signaling in adipose tissue may be required for normal suppression of insulin resistance, and nondiabetic plasma treatment of SVFs that stimulates IL-10 production could be used as a novel cell therapy strategy to decrease proinflammatory cytokine expressions in the adipose tissue and liver, reduce systemic CCL2 levels, and improve insulin resistance in diabetics. This evidence concerns the gene IL10 and diabetes mellitus.